Literature DB >> 31279323

Effect of IL2RA and IL2RB gene polymorphisms on lung cancer risk.

Zhuoqi Jia1, Zhe Zhang2, Qi Yang3, Chunni Deng2, Daxu Li4, Le Ren5.   

Abstract

BACKGROUND: Inflammation is crucial for lung cancer development. Variants of multiple genes in inflammation pathways may lead to susceptibility to lung cancer. In the present study, we aimed to assess the influence of polymorphisms in inflammation-related genes (IL2RA and IL2RB) on lung cancer risk.
METHODS: A total of 507 patients with lung cancer and 503 healthy controls were genotyped for seven polymorphisms of IL2RA and IL2RB using the Agena MassARRAY platform. We evaluated the relationship of the genotypes with lung cancer susceptibility using odds ratio (OR), 95% confidence interval (95% CI) and chi square test.
RESULTS: We found that IL2RA rs12722498 was significantly associated with a decreased risk of lung cancer in dominant (p = 0.040, OR = 0.71, 95% CI = 0.51-0.98), additive (p = 0.016, OR = 0.68, 95% CI = 0.50-0.93) and allele (p = 0.019, OR = 0.69, 95% CI = 0.51-0.94) models. After stratification analysis, the results showed that IL2RA rs12569923 (non-smokers), IL2RA rs791588 (≤60 years old, non-drinkers, BMI < 24 kg/m2), IL2RA rs12722498 (≤60 years old, non-drinkers, BMI < 24 kg/m2, female) and IL2RB rs2281089 (female, stage) significantly decreased the risk of lung cancer. Additionally, the haplotypes of rs12569923 and rs791588 in IL2RA had strong relationships with lung cancer in the subgroups of BMI < 24 kg/m2, age ≤ 60 years old, non-smokers and non-drinkers.
CONCLUSION: Our results showed that the IL2RA and IL2RB polymorphisms were associated with lung cancer risk in the Chinese Han population, which suggests roles for IL2RA and IL2RB polymorphisms in lung cancer.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IL2RA; IL2RB; Lung cancer; Polymorphisms; Susceptibility

Mesh:

Substances:

Year:  2019        PMID: 31279323     DOI: 10.1016/j.intimp.2019.105716

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.

Authors:  Zifu Yao; Anqi Lin; Yonglin Yi; Weitao Shen; Jian Zhang; Peng Luo
Journal:  Drug Des Devel Ther       Date:  2022-06-03       Impact factor: 4.319

2.  Epigenetic Alterations Associated with the Overall Survival and Recurrence Free Survival among Oral Squamous Cell Carcinoma Patients.

Authors:  Yasmen Ghantous; Aysar Nashef; Imad Abu-Elnaaj
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

3.  Downregulation of miR-497-5p Improves Sepsis-Induced Acute Lung Injury by Targeting IL2RB.

Authors:  Wei Lou; Jieping Yan; Weisi Wang
Journal:  Biomed Res Int       Date:  2021-04-12       Impact factor: 3.411

4.  IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer.

Authors:  Guangyao Li; Yandong Wang; Ya Cheng
Journal:  J Oncol       Date:  2022-04-29       Impact factor: 4.501

5.  A Novel Inflammatory Response-Related Gene Signature Improves High-Risk Survival Prediction in Patients With Head and Neck Squamous Cell Carcinoma.

Authors:  Yanxun Han; Zhao Ding; Bangjie Chen; Yuchen Liu; Yehai Liu
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.